array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2445)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(116) "Adium announces an exclusive distribution agreement with Regeneron for the commercialization of Cemiplimab in Brazil"
["snippet_en"]=>
string(148) "Pharmaceutical company Adium announces exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron, for Libt"
["url"]=>
string(136) "https://saludnews.net/adium-anuncia-un-acuerdo-de-distribucion-exclusiva-con-regeneron-para-la-comercializacion-de-cemiplimab-en-brasil/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f9806725-d463-475f-baf3-e64255bac539"
["source"]=>
string(13) "saludnews.net"
["publication_date"]=>
string(10) "2024-03-30"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[1]=>
array(7) {
["title_en"]=>
string(112) "2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron | TSVT Stock News"
["snippet_en"]=>
string(229) "2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma."
["url"]=>
string(115) "https://www.stocktitan.net/news/TSVT/2seventy-bio-announces-completion-of-oncology-and-autoimmune-65ex5m9fekls.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/dd4bdefa-472d-41a7-9009-ab29959775ab"
["source"]=>
string(14) "stocktitan.net"
["publication_date"]=>
string(10) "2024-03-20"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[2]=>
array(7) {
["title_en"]=>
string(30) "GENESIS-PHARMA | Business Wire"
["snippet_en"]=>
string(147) "GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta"
["url"]=>
string(88) "https://via.ritzau.dk/pressemeddelelse/13787386/genesis-pharma?publisherId=90456&lang=en"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/da91a8de-3b23-4b5e-a877-b5a3d333fcec"
["source"]=>
string(9) "ritzau.dk"
["publication_date"]=>
string(10) "2024-03-01"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[3]=>
array(7) {
["title_en"]=>
string(75) "Regeneron Pharmaceuticals inks $100M deal to develop gene-editing therapies"
["snippet_en"]=>
string(117) "The deal gives Regeneron access to Mammoth Biosciences' gene editing systems, which can be used to cut DNA sequences."
["url"]=>
string(114) "https://www.crainsnewyork.com/health-pulse/regeneron-pharmaceuticals-inks-100m-deal-develop-gene-editing-therapies"
["image_url"]=>
NULL
["source"]=>
string(17) "crainsnewyork.com"
["publication_date"]=>
string(10) "2024-02-04"
["categories"]=>
array(1) {
[0]=>
string(15) "Deals & Tenders"
}
}
[4]=>
array(7) {
["title_en"]=>
string(128) "Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries"
["snippet_en"]=>
string(158) "/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international..."
["url"]=>
string(182) "https://www.prnewswire.co.uk/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a5536b51-142d-4a07-8c9b-f46a94f9b2c2"
["source"]=>
string(16) "prnewswire.co.uk"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(3) {
[0]=>
string(24) "Access and affordability"
[1]=>
string(13) "Collaboration"
[2]=>
string(15) "Deals & Tenders"
}
}
[5]=>
array(7) {
["title_en"]=>
string(69) "Meharry and Big Pharma announce $80 million deal for genetics project"
["snippet_en"]=>
string(131) "The investment at Meharry will include the creation of a genetics research center and programs to encourage students to study STEM."
["url"]=>
string(136) "https://eu.tennessean.com/story/news/health/2023/10/19/meharry-and-big-pharma-announce-80-million-deal-for-genetics-project/71219652007/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6eb4cfc7-bed9-48e8-9a36-ac7d25f2131a"
["source"]=>
string(14) "tennessean.com"
["publication_date"]=>
string(10) "2023-10-19"
["categories"]=>
array(4) {
[0]=>
string(17) "Academic Research"
[1]=>
string(5) "R & D"
[2]=>
string(13) "Collaboration"
[3]=>
string(15) "Deals & Tenders"
}
}
[6]=>
array(7) {
["title_en"]=>
string(85) "Alliance Between Regeneron Genetics and Tec Will Help the Knowledge of Mexican Genome"
["snippet_en"]=>
string(109) "The university signed an agreement with the international company that will help analyze the genetic samples."
["url"]=>
string(76) "https://tecscience.tec.mx/en/health/regeneron-genetics-and-tec-de-monterrey/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d5219125-ad38-4ae5-8cf2-c9dac22cb4a1"
["source"]=>
string(6) "tec.mx"
["publication_date"]=>
string(10) "2023-09-21"
["categories"]=>
array(2) {
[0]=>
string(13) "Collaboration"
[1]=>
string(15) "Deals & Tenders"
}
}
[7]=>
array(7) {
["title_en"]=>
string(57) "Celularity signs on to do contract research for Regeneron"
["snippet_en"]=>
string(123) "Celularity announced Tuesday morning that it will do contract research for Regeneron on the Tarrytown, NY-based company’s"
["url"]=>
string(77) "https://endpts.com/celularity-signs-on-to-do-contract-research-for-regeneron/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a068159b-a276-4997-9b98-0d9a7ed014d5"
["source"]=>
string(10) "endpts.com"
["publication_date"]=>
string(10) "2023-08-29"
["categories"]=>
array(3) {
[0]=>
string(17) "Business Disputes"
[1]=>
string(17) "Academic Research"
[2]=>
string(15) "Deals & Tenders"
}
}
[8]=>
array(7) {
["title_en"]=>
string(88) "Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron"
["snippet_en"]=>
string(293) "Celularity to provide research support for Regeneron 's targeted, allogeneic, chimeric antigen receptor( CAR) T-cell therapyAgreement underscores Celularity 's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023( GLOBE NEWSWIRE) -- Celularity Inc.( Nasdaq: CELU)("
["url"]=>
string(95) "https://finance.yahoo.com/news/celularity-announces-multi-research-collaboration-130000885.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/e1f0da82-af34-42ad-85f5-8b85e1a120e4"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-08-29"
["categories"]=>
array(3) {
[0]=>
string(17) "Academic Research"
[1]=>
string(13) "Collaboration"
[2]=>
string(15) "Deals & Tenders"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(101)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(30)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2445 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma.
/PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international...
Celularity to provide research support for Regeneron 's targeted, allogeneic, chimeric antigen receptor( CAR) T-cell therapyAgreement underscores Celularity 's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023( GLOBE NEWSWIRE) -- Celularity Inc.( Nasdaq: CELU)(
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
